Increased bone marrow angiogenesis is a poor prognostic marker in patients with chronic myelogenous leukemia (CML). Allogeneic stem cell transplantation (ASCT) can be curative for patients with CML. Studies in myeloma have shown persistent increased bone marrow microvessel density (MVD) after autologous transplantation. It is not clear if abnormal bone marrow angiogenesis persists following a curative intervention like allogeneic transplantation. We evaluated MVD from bone marrow samples obtained just prior to and at 3-5 months after ASCT in 24 patients with CML. The median MVD pretransplant was 14 (4-37), with 11 patients having highgrade angiogenesis and 13 having low grade. The median post transplant MVD was 20 (range 5-36), with 12 patients having high-grade angiogenesis and 12 low grade. The median time between biopsies was 4 months (range 1-6 months). The microvessels in the post transplant bone marrow appeared morphologically different with striking dilatation and sinusoidal appearance compared to the pretransplant marrow. However, there was no significant change in MVD following transplant (P ¼ 0.8, paired t-test). Abnormal bone marrow angiogenesis appears to persist in the bone marrow following ASCT for CML, at least in the short term.
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1,2 The ability of tumors to enhance angiogenesis in tumor tissue has been associated with increased capability for invasion and metastasis. Increasing levels of tumor angiogenesis have been correlated with poor prognosis for a variety of solid tumors in humans. [3] [4] [5] [6] During recent years, studies have highlighted the importance of increased bone marrow angiogenesis in hematological malignancies. As in solid tumors, new vessel formation (occurring in the bone marrow) appears to play an integral role in the pathophysiology of leukemias, 7-15 myeloma [16] [17] [18] and in myelofibrosis with myeloid metaplasia. 19 Increased bone marrow angiogenesis has been shown to have prognostic value in many of these hematological disorders. Immunohistochemical stains using antibodies against endothelial antigens like CD34, VIII-related antigen, CD31 and others allow excellent visualization of the microvessels. 20 Quantification of angiogenesis can be achieved in terms of the number of microvessels in a defined area of the marrow (microvessel density; MVD) or the percentage of unit surface area occupied by microvessels. 21, 22 Different approaches have been adopted for estimating the degree of angiogenesis including visual grading, 23 use of grids for counting 16 and computerized image subtraction analysis. 24 Chronic myelogenous leukemia (CML) is characterized by proliferation of myeloid progenitor cells carrying a distinct genetic abnormality in the form of t(9:22) translocation ultimately resulting in the generation of the oncogene bcr-abl. Previous studies have demonstrated the presence of increased bone marrow angiogenesis in patients with CML. [12] [13] [14] [15] As in the other hematological malignancies with a similar finding, increased bone marrow angiogenesis appears to have prognostic value in CML, predicting both progression and survival.
14 Malignant cells in CML may have a direct role in the formation of these new blood vessels, and studies suggest that inhibition of angiogenesis may at least in part explain the mechanism of action of drugs used in CML. 25 Although new biological agents like imatinib mesylate can result in dramatic clinical improvement in patients with CML, allogeneic stem cell transplant is the only modality that has resulted in a cure and long-term disease-free survival. Given the important role of the enhanced vascular network in the biology of this disease, we examined the effect of allogeneic transplant on bone marrow angiogenesis in CML.
Methods and materials

Patients
Patients who underwent allogeneic stem cell transplantation (ASCT) at our institution for CML, in whom archived bone marrow biopsy tissue from before and after the transplant was available, were identified. Details regarding the clinical course and transplantation were obtained from review of medical records. All patients had given written informed consent for research use of bone marrow specimens. Approval for the study was obtained from the Mayo Institutional Review Board in accordance with federal regulations and the Declaration of Helsinki.
Microvessel staining
Paraffin-embedded bone marrow biopsy blocks were used to prepare slides for MVD determination using methods that have been described previously. 16, 26 Immunohistochemical staining for factor VIII-related antigen (von Willebrand factor) was performed by a labeled streptavidin-biotin peroxidase method on the Ventana ES automated immunohistochemistry stainer (Ventana Medical Systems, Tucson, AZ, USA), using buffers and detection reagents supplied by the manufacturer. Deparaffinized tissue sections were subjected to protease digestion on the instrument with Protease 2 for 12 min prior to immunostaining. The primary antibody (DAKO A0082, Dako, Carpinteria, CA, USA, diluted 1:2000) was incubated with tissue sections for 24 min. The AEC (amino ethyl carbazole) detection kit (Ventana Systems) was used for antigen visualization; sections were counterstained with a light hematoxylin and then cover slipped with Kaiseri's (Mayo Medical Laboratories, Rochester, MN, USA) glycerol jelly. Paraffin sections of well-vascularized tonsil were run with each batch to serve as a positive control, and a section stained with nonimmune rabbit immunoglobulin was used as a negative control for each sample tested.
Microvessel density determination
Bone marrow angiogenesis was estimated by microscopic evaluation in terms of MVD. Slides stained with factor VIII-ReAg were first scanned under low power ( Â 100) in order to determine three 'hot spots' defined as areas with a maximum number of microvessels. This technique has been evaluated before and has been found to be very reproducible. 16, 27 These three areas are then evaluated at Â 400 magnification using a Â 40 objective and a Â 10 ocular lens. All the slides were read by the same author using the same microscope for consistency. The pre-and post treatment slides were examined in a blinded manner to eliminate bias. Large vessels and vessels within the bony spicules and under the periosteum were excluded. Areas of staining without any discrete breaks were counted as single vessels. Presence of a lumen or presence of red cells was not required for the identification of microvessels. Any highlighted endothelial cell or cell cluster separate from the adjacent microvessels was counted as a distinct vessel. The number of vessels in one Â 400 field was determined at each hot spot area and their average was taken as the MVD expressed as MVD per field. Patients were divided into two grades of bone marrow angiogenesis based on the MVD: low (MVD o20) and high (MVD X20). A cutoff of 20 was used based on results from our previous studies.
Statistical analysis
Paired t-test was used for paired comparison of pre-and post transplant MVD. Kaplan-Meier analysis was used to estimate survival and log-rank test was used to compare survival curves. The Fisher's exact test was used to compare differences in nominal variables. All tests were two-tailed and a P of o0.05 was considered significant for all comparisons.
Results
A total of 24 patients with CML, 14 (58%) males, with a median age of 39 years (mean 38, range 21-52) were studied. The clinical and laboratory features are given in Table 1 . Complete follow-up was available for all patients. Median duration to transplant from diagnosis was 6 months (mean 13, range 2-57). In all, 21 patients were in their first chronic phase, two in the second chronic phase and one in accelerated phase prior to transplant. The median follow-up for these patients from transplant was 39 months (mean 40 months, range 1-9 years). Of these patients, 18 (67%) were alive at the time of last follow-up, and in CR. The 5-year estimated survival for the entire group was 70%.
The median MVD pre-transplant was 14.5 (mean 18, range 5-37). A total of 11 patients (46%) had high-grade angiogenesis compared to 13 (54%) with low-grade angiogenesis. Immunostainings with vWF, demonstrating the microvessel in the bone marrow before and after therapy in two representative patients, are shown in Figure  1(2a,b and 3a,b) . The median duration to the post transplant biopsy was 4 months from transplant (mean 4 months, range 1-6 months). The median MVD at the end of treatment was 19.5 (mean 18.5, range 5-32). Half of the patients had high-grade MVD post transplant. There was Angiogenesis in chronic myelogenous leukemia no significant difference between the pre-and post therapy MVD (P ¼ 0.87 for the paired comparison). Figure 2 is a scatterplot showing the relation between pre-and post therapy MVD. The MVD increased in 12 (50%) patients (median increase 8, range 1-22), decreased in 10 (42%) patients (median decrease 10, range 3-18) and remained unchanged in two (8%). The blood vessels in the post transplant marrow, when compared to the pre-transplant marrow, were significantly dilated and had a sinusoidal appearance ( Figure 1(2b and 3b) ). Most of the microvessels in pre-transplant marrows ranged from 7 to 15 mm in maximal diameter, and the enlarged blood vessels in the post transplant marrows ranged up to 50 mm in diameter. A direct quantitative comparison of the preand post transplant vessel size was difficult due to the variability in the size of the vessels across the fields. Four of 11 patients in the high-grade pre-transplant MVD group had died compared to 2 of 13 patients in the low-grade group; however, this difference was not statistically significant. The cause of death included GVHD in three patients, infection in one and multiorgan failure in the remaining two. No relationship was seen between initial MVD or the degree of change in MVD and development of acute or chronic GVHD (Table 2) .
Discussion
Angiogenesis or formation of new blood vessels in tumor tissue is a multistep process that appears to be tumor driven and involves the proliferation and migration of endothelial cells as well as breakdown of surrounding matrix elements. 1, 28, 29 It is believed to be orchestrated by various angiogenic cytokines like VEGF, bFGF, HGF and TGFb expressed by the tumor as well as different matrix metalloproteinases secreted by the tumor tissue. 30 Increasing angiogenic potential appears to correlate well with increased invasiveness as well as proliferative capability of both solid and hematological malignancies. 31 Among the hematological malignancies, multiple myeloma is probably the most studied in terms of tumor angiogenesis and its implications. 16, 32 However, several studies have demonstrated increased bone marrow angiogenesis in patients with CML. 12, 14, 15 In a study evaluating bone marrow vascularity in acute and chronic leukemias, patients with CML had the highest degree of marrow angiogenesis compared to CLL, acute myeloid and lymphoid leukemias and MDS, other disease states that have been associated with increased marrow angiogenesis. 12 Other studies have shown an increase in the marrow angiogenesis, corresponding to the clinical progression from chronic phase to blastic phase of CML. Note the dilated microvessels post transplant, most obvious in 3b (block arrows). Also note the large para-trabecular vessels in 1a and 3a, which are not included in the microvessel counts. Table 2 Relationship of acute and chronic GVHD to MVD preand post transplant 
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Increased bone marrow angiogenesis appears to be a poor prognostic factor in CML similar to what has been seen with other malignancies. Its prognostic value in the setting of CML appears to be independent of other known prognostic factors.
14 Patients in chronic phase CML with increased MVD appear to be at a higher risk for progression to blastic phase and have a lower overall survival as well. There also appear to be morphological variations in the marrow microvessels of CML compared to normal controls as well as between different stages of the disease.
14 Serum levels of angiogenic cytokines like VEGF are elevated in CML and are believed to play a role in the initiation and progression of marrow angiogenesis. 12 The elevated VEGF in CML is thought to be the result of increased secretion of the cytokine by megakaryocytes and myeloid blasts. 33 Recent studies have suggested a prognostic value in CML for Tie-1 expression, a molecule that is involved in the regulation of angiogenesis. 34 The bcr-abl construct has also been identified in the endothelial cells of marrow blood vessels, strengthening the hypothesis that these microvessels are intricately involved in the pathophysiology of the disease. 35 In vitro studies have demonstrated increased secretion of VEGF by tumor cell lines transfected with the bcr-abl construct. The increased secretion of VEGF may be at least in part mediated through hypoxiainducible factor (HIF-1), a strong transcriptional regulator of VEGF gene expression. 36 This increased secretion can be inhibited by the bcr-abl-specific tyrosine kinase inhibitor STI571 (imatinib mesylate) in a dose-dependent fashion. 25 Thus, at least part of the activity of imatinib mesylate may be mediated by downregulation of angiogenic cytokines in these clonal populations. Although VEGF appears to be the dominant cytokine involved in increased angiogenesis in CML, bcr-abl-positive cells are also capable of secreting increased amounts of FGF-2, HGF and IL-8, other known angiogenic cytokines. 37 Transfection of cell lines with the bcr-abl construct can also lead to increased secretion of matrix metalloproteinases MMP-2 and MMP-9. 37 Introduction of imatinib mesylate has revolutionized the therapy of CML. However, ASCT remains the only approach that has resulted in long-term cure of this disease. In this study, we have for the first time examined the effect of ASCT on bone marrow MVD in patients with CML. We did not find any significant change in the marrow MVD following ASCT. We also did not observe a significant prognostic value for angiogenesis as suggested in other studies, which may be a reflection of the small sample size. The implications of persistent increased MVD in these patients remain unclear. At least in this small group of patients, the change in MVD did not correlate in any manner with the risk of relapse. It is possible that the endothelial cells may be functionally inactive, especially given that the paracrine interactions from the tumor cells are removed as a result of cytoreductive therapy. It is also possible that evaluation of bone marrow at a more remote time point from transplant would demonstrate a significant change. Unfortunately, since routine bone marrow biopsies are no longer obtained as part of long-term follow-up in these patients, they could not be assessed in this study.
The trend toward slightly higher MVD in the post transplant marrow is likely a result of the enlargement of existing vessels due to loss of the surrounding hypercellular marrow, thus enabling easier identification on microscopy. Widening of bone marrow microvessels following induction therapy has been observed in patients with acute leukemia and is probably related to the unpacking of the marrow from loss of leukemic cells. 11 The findings of this study are similar to what we have observed in patients with multiple myeloma undergoing autologous stem cell transplantation or conventional chemotherapy. 23 However, these two disorders are treated by very different approaches and the findings may not be necessarily comparable. The MVD as measured by the current method is a reflection of the intervascular distance. It is possible that differences in the rate of apoptosis of the endothelial cells and the tumor cells following therapy can lead to findings of decreased, same or increased MVD following therapy as has been reported by Folkman and co-workers. 38, 39 In the context of solid tumors, when endothelial cell death lags behind that of the malignant cells, the existing endothelial cells become compacted into a smaller volume, appearing as increased MVD by cross-sectional estimation. Although this explanation may not hold true in the case of bone marrow, where the volume is held constant by the bone structure, differences in the rate of destruction of the endothelial and malignant cells may partly explain the findings. In conclusion, we did not observe any significant change in bone marrow MVD following allogeneic stem cell transplant in patients with CML. Ongoing studies will shed further light on the significance of these persistent vessels. This study once again underscores the fact that regression of bone marrow blood vessels should not be used as a biological end point for response to therapy.
